Dr. Barbara Fleming-phillips, MD
Family Medicine (Family Medicine Physician)
740 S Limestone
Lexington, KY 40536
Who else practices at this address →
Fayette County includes mental health (15% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2007
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
KY license 26980 -
Internal Medicine Physician
KY license 26980
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 4 companies. The companies reported $781,551 in research payments for these studies, mostly to the institutions running them.
- A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
Eli Lilly and Company · Active, not recruiting · NCT06859268 - A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 Co administered with a GLP 1 Receptor Agonist in Participants with Type 2 Diabetes and Overweight…
AstraZeneca UK Limited - A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes
Boehringer Ingelheim Pharmaceuticals, Inc. - A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mel…
Boehringer Ingelheim Pharmaceuticals, Inc. - A phase 2, parallel-group, double-blind study to investigate the safety and tolerability of LY3549492 compared with placebo in adult participants 55 to 80 years of age and bmi within 22 to 25 kg/M2
Eli Lilly and Company - A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes
Boehringer Ingelheim International GmbH - A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mel…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.